SVB Wealth LLC Takes $181,000 Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

SVB Wealth LLC bought a new position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 60,554 shares of the biopharmaceutical company’s stock, valued at approximately $181,000. SVB Wealth LLC owned approximately 0.05% of Esperion Therapeutics at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Simplicity Solutions LLC bought a new stake in shares of Esperion Therapeutics in the 3rd quarter valued at approximately $30,000. Pinnacle Associates Ltd. increased its holdings in Esperion Therapeutics by 15.7% during the 3rd quarter. Pinnacle Associates Ltd. now owns 289,123 shares of the biopharmaceutical company’s stock worth $283,000 after purchasing an additional 39,285 shares during the period. Chicago Partners Investment Group LLC purchased a new position in shares of Esperion Therapeutics in the 3rd quarter valued at $29,000. Jacob Asset Management of New York LLC purchased a new position in shares of Esperion Therapeutics in the 3rd quarter valued at $59,000. Finally, Monaco Asset Management SAM increased its holdings in shares of Esperion Therapeutics by 68.5% in the 3rd quarter. Monaco Asset Management SAM now owns 1,171,779 shares of the biopharmaceutical company’s stock valued at $1,148,000 after acquiring an additional 476,477 shares during the period. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Price Performance

Shares of Esperion Therapeutics stock opened at $2.09 on Wednesday. Esperion Therapeutics, Inc. has a 1-year low of $0.70 and a 1-year high of $3.40. The stock has a market cap of $395.85 million, a P/E ratio of -0.99 and a beta of 0.84. The stock’s 50 day simple moving average is $2.44 and its 200-day simple moving average is $1.98.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03. The firm had revenue of $32.25 million for the quarter, compared to analyst estimates of $26.84 million. During the same quarter last year, the company earned ($0.76) earnings per share. As a group, research analysts expect that Esperion Therapeutics, Inc. will post -0.68 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on ESPR shares. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, April 10th. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a report on Monday, March 25th. Finally, Bank of America lowered Esperion Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, January 3rd. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $9.33.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.